Consortia
Memberships
Plan S
ASAP is a proud member of Plan S, an initiative for Open Access publishing. The plan is supported by cOAlition S, an international consortium of research funding and performing organizations. Plan S requires that, from 2021, scientific publications that result from research funded by public grants must be published in compliant Open Access journals or platforms.
Open Research Funders Group
ASAP is proud to join alongside philanthropic organizations as a member of The Open Research Funders Group (ORFG). ORFG is a partnership of funding organizations committed to the open sharing of research outputs and other forms of scholarship. The ORFG has two primary programmatic pillars: (1) engaging philanthropies in a community of practice to develop, implement, oversee, and advance strategies that accelerate access to funded research, including papers and data; and (2) serving as the funders’ voice in cross-sector discussions about open research policies, incentives, infrastructure, and good practices.
AMP® PDRD
The Accelerating Medicine Partnership in Parkinson’s Disease and Related Disorders (AMP® PDRD) is a public-private partnership between the National Institutes of Health (NIH), multiple biopharmaceutical and life science companies, and nonprofit organizations. Managed through the Foundation for the NIH (FNIH), AMP® PDRD aims to harmonize Parkinson’s and related disease datasets across the community with the goal of identifying and validating diagnostic, prognostic, and/or progression biomarkers for Parkinson’s disease, with an emphasis on broadening data sharing in the biomedical community to advance Parkinson’s research. ASAP is proud to be a partner in the AMP® PDRD effort to broaden data sharing in the biomedical community to advance Parkinson’s research. Both GP2 and PPMI cohorts share their data on this platform.
News & Updates
Our initiative is accelerating the pace of discovery for Parkinson’s disease through collaboration, research-enabling resources, and data sharing.
2025: A Year in Review
December 17, 2025
We are proud to share how we impacted the Parkinson’s disease research field in 2025. Read our report to see how the infrastructure and processes we established are changing the way science is done and are generating significant momentum.
Learn More
100,000 Participants and Counting – Massive Global Genetic Dataset Powers Discoveries in Parkinson’s Disease
December 1, 2025
Researchers have reached a major milestone in the effort to understand and treat Parkinson’s disease: more than 100,000 DNA samples from study participants around the world have now been genotyped and sequenced through the Global Parkinson’s Genetics Program (GP2).
Learn More
GP2’s 11th Data Release
December 1, 2025
GP2 announced its 11th data release at the end of 2025, bringing the total to over 100,000 samples from individuals worldwide, making it one of the most comprehensive and globally representative PD datasets to date.
Learn More